New frontiers in the therapeutic management of transplant rejection

Current Pharmaceutical Design

Volumn 12, Issue 19, 2006, Pages 2383-2395

  De Sanctis, Juan B ^a,d   Garmendia, Jenny V ^a   Radzioch, Anna ^b   Radzioch, Danuta ^c  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d Central University of Venezuela Miami Campus   (United States)

Author keywords

Acute transplant rejection; Arachidonic acid metabolism; Chronic transplant rejection; Graft rejection; Hyperacute transplant rejection; Immune response; Transplant; Xenotransplant

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ALPHA GALACTOSYLCERAMIDE; APOPTOSIS INHIBITOR; ARACHIDONIC ACID; ATORVASTATIN; CD40 LIGAND MONOCLONAL ANTIBODY; COMPLEMENT INHIBITOR; CYCLOSPORIN A; CYTOKINE; FINGOLIMOD; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOPHILIN; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROGESTERONE; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN D2 DERIVATIVE; PROSTAGLANDIN D2 RECEPTOR AGONIST; RAPAMYCIN; ROSUVASTATIN; SIMVASTATIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRAFT REJECTION; ARACHIDONIC ACID METABOLISM; CHRONIC GRAFT REJECTION; CLINICAL IMMUNOLOGY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERACUTE GRAFT REJECTION; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; XENOTRANSPLANTATION;

ANIMALS; ARACHIDONIC ACID; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAP KINASE SIGNALING SYSTEM;

EID: 33745743907     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777698990     Document Type: Review

References (100)

1. Platt JL, Nagayasu T. Current status of xenotransplantation. Clin Exp Pharmacol Physiol 1999; 26: 1026-32
2. Douillard P, Cuturi MC, Brouard S, Josien F, Soulillou JP. T cell receptor repertoire usage in allotransplantation: an overview. Transplantation 1999; 68: 913-21.
3. Soares MP, Lin Y, Sato K, Stuhlmeier KM, Bach FH. Accommodation. Immunol Today 1999; 20: 434-7.
4. Vogelsang GB, Lee L, Bensen-Kennedy DM. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med 2003; 54: 29-52.
5. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19: 225-252.
6. Kansu E. The pathophysiology of chronic graft-versus-host disease. Int J Hematol 2004; 79: 209-15.
7. Rocha PN, Plumb TJ, Crowley SD, Coffman TM. Effect mechanisms in transplant rejection. Immunol Rev 2003; 196: 51-64.
8. Bothwell AL. Characterization of the human antiporcine immune response: a prerequisite to xenotransplantation. Immunol Res 1999; 19: 233-43.
9. Pham MX, Hunt SA, Johnson FL. Cardiac xenotransplantation. Coron Artery Dis 2004; 15: 99-105.
10. Koch CA, Khalpey ZI, Platt JL. Humoral immunity in xenotransplantation: B-cell tolerance and accomodation. Curr Opin Organ Transpl 2004; 9: 170-175.
11. Mollnes TE, Fiane AE. Perspectives on complement in xenotransplantation. Mol Immunol 2003, 40: 135-143.
12. Saadi S, Takahashi T, Holzknecht RA, Platt JL. Pathways to acute humoral rejection. Am J Pathol 2004; 164(3): 1073-80.
13. Kuwaki K, Knosalla C, Dor FJ, Gollackner B, Tseng YL, Houser S, et al. Suppression of natural and elicited antibodies in pig-to-baboon heart transplantation using a human anti-human CD154 mAb-based regimen. Am J Transplant 2004; 4: 363-72.
14. Cavanaugh KL, Rabb H. T cells and signaling pathways in ischemia, and reperfusion injury Curr Opin Organ Transplant 2004; 9: 132-138.
15. Cozzi E, Seveso M, Ancona E. Pathogenesis and pathology of different types of xenotransplant rejection. Curr Opin Organ Transplat 2004; 9: 163-169.
16. Sindhi R, Magill A, Manavalan S, Yost M, Halusczyak C, Zeevi A. Peripheral lymphocyte markers as surrogate measures of immunosuppression and post-transplant clinical studies. Clin Applied Immunol Rev 2004; 4: 225-238.
17. van der Vliet HJ, Molling JW, von Blomberg BM, Nishi N, Kolgen W, van den Eertwegh AJ, et al. The immunoregulatory role of CDld-restricted natural killer T cells in disease. Clin Immunol 2004; 112: 8-23.
18. Young NT. Immunobiology of natural killer lymphocytes in transplantation. Transplantation 2004; 78: 1-6.
19. Raab M, Daxecker H, Karimi A, Markovic S, Cichna M, Markl P, et al. In vitro effects of mycophenolic acid on the nucleotide pool and on die expression of adhesion molecules of human umbilical vein endothelial cells. Clin Chim Acta 2001; 310: 89-98.
20. Khan BD. Concepts in Solid organ transplantation. In: Rich RR, Fleisher TA, Shearer WT, Kotzin BL, Schroeder HW. Ed. Clinical Immunology Ptrinciples and Practice. London, Mosby 2001; pp. 89.1-89.15.
21. Majewski AC, Hansen PJ. Progesterone inhibits xenogeneic transplants in the sheep utrerous. Horm Res 2002, 58: 128-35.
22. Hull KM, Boumpas DT. Immunomodulating pharmaceuticals. In: Rich RR, Fleisher TA, Shearer WT, Kotzin BL, Schroeder HW. Ed. Clinical Immunology Principles and Practice. London, Mosby, 2001; pp. 110.1-110.14.
23. Cristillo AD, Bierer BE. Immunophilins and immunophilins binding agents. In: Rich RR, Fleisher TA, Shearer WT, Kotzin BL, Schroeder HW. Ed. Clinical Immunology Ptrinciples and Practice. London, Mosby, 2001; pp. 111.1-111.13.
24. Goldstein DR, Tesar BM, Akira S, Lakkis FG. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 2003; 111: 1571-8.
25. Sugerman PB, Faber SB, Willis LM, Petrovic A, Murphy GF, Silberstein D, et al. Kinetics of gene expression in murine cutaneous graft-versus-host diseases. Am J Pathol 2004; 164: 2189-202.
26. Rosenberg AS, Mizuochi T, Sharrow SO, Singer A. Phenotype, specificity, and function of T subsets and T cell interactions involved in skin allograft rejection. J Exp Med 1987; 165, 1296-1315.
27. Kreisel D, Krupnick AS, Balsara KR, Riha, M, Gelman AE, Popma SH, et al. Mouse vascular endothelium activates CD8+ T lymphocytes in a B7-dependent fashion. J Immunol 2002; 169: 6154-61.
28. Kreisel D, Krasinskas AM, Krupnick AS, Gelman AE, Balsara KR, Popma SH, et al. Vascular Endothelium Does Not Activate CD4+ Direct Allorecognition in Graft Rejection. J Immunol 2004; 173: 3027-34.
29. Adler SH, Turks LA. Immunotherapy as a means to induce transplantation tolerance. Curr Opin Immunol 2002; 14: 660-5.
30. Barker RN, Erwig LP, Hill KS, Devine A, Pearce WP, Rees AJ. Antigen presentation by macrophages is enhanced by the uptake of necrotic, but not apoptotic, cells. Clin Exp Immunol 2002; 127: 220-5.
31. De Sanctis JB, Blanca I, Radzioch D, Bianco N. Lipoprotein metabolism and NK Function. Recent Res Devel Immunol 1999; 1 (II), 483-496.
32. Vongwiwatana A, Tasanarong A, Hidalgo LG, Halloran PF. The role of B cells and alloantibody in the host response to human organ allografts. Immunol Rev 2003; 196: 197-218.
33. Rocha PN, Butterly DW, Greenberg A, Reddan DN, Tuttle-Newhall J, Collins BH, et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003; 75(9): 1490-5.
34. Brandle D, Joergensen J, Zenke G, Burki K, Hof RP. Contribution of donor-specific antibodies to acute allograft rejection: evidence from B cell-deficient mice. Transplantation 1998; 65: 1489-93.
35. Wasowska BA, Qian Z, Cangello DL, Behrens E, Van Tran K, Layton J, et al. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice. Transplantation 2001; 71: 727-36.
36. Demirci G, Amanullah F, Kewalaramani R, Yagita H, Strom TB, Sayegh MH, et al. Critical role of OX40 in CD28 and CD154-independent rejection. J Immunol 2004; 172(3): 1691-8.
37. Yuan X, Salama AD, Dong V, Schmitt I, Najafian N, Chandraker A et al. The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo. J Immunol 2003; 170(6): 2949-55.
38. Pratt JR Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002; 8: 582-7.
39. Thompson C, Powrie F. Regulatory T cells. Curr Opin Pharmacol 2004; 4: 408-14.
40. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-6.
41. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and downregulation of Smad7. J Immunol 2004; 172: 5149-53.
42. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299(5609):1057-61.
43. Uraushihara K, Kanai T, Ko K, Totsuka T, Makita S, Iiyama I, et al. Regulation of murine inflammatory bowel disease by CD25+ and CD25- CD4+ glucocorticoid-induced TNF receptor family-related gene+ regulatory T cells. J Immunol 2003; 171(2): 708-16.
44. Fisson S, Darrasse-Jeze G, Litvinova E, Septier F, Klatzmann D, Liblau R, et al. Continuous activation of antoreactive CD4+ CD25+ regulatory T cells in the steady state. J Exp Med 2003; 198: 737-46.
45. Higgins SC, Lavelle EC, McCann C, Keogh B, McNeela E, Byrne P, et al. Toll-like receptor 4-mediated innate IL- 10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology. J Immumol 2003; 171: 3119-27.
46. Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 2004; 22: 361-403.
47. Kudlacz E, Perry B, Sawyer P, Conklyn M, McCurdy S, Brissette W, et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant 2004; 4: 51-7.
48. Tkaczuk J, Yu CL, Baksh S, Milford EL, Carpenter CB, Burakoff SJ, et al. Effect of anti-IL-2Ralpha antibody on IL-2-induced Jak/STAT signaling. Am J Transplant 2002; 2: 31-40.
49. Andreucci M, Michael A, Kramers C, Park KM, Chen A, Matthaeus T, et al. Renal ischemia/reperfusion and ATP depletion/repletion in LLC-PK(1) cells result in phosphorylation of FKHR and FKHRL1. Kidney Int 2003; 64: 1189-98.
50. Sack MN, Yellon DM. Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation. J Am Coll Cardiol 2003; 41: 1404-7.
51. Jacobsohn DA, Vogelsang GB. Anti-cytokine therapy for the treatment of graft-versus-host disease. Curr Pharm Des 2004; 10(11):1195-205.
52. Alberu J, Richud-Patin Y, Vazquez-Lavista LG, de Leo C, Guzman-Rodriguez H, Mancilla E, et al. In vivo IL-10 and TGF-beta production by PBMC from long-term kidney transplant recipients with excellent graft function: a possible feedback mechanism participating in immunological stability. Clin Transplant 2004; 18: 174-8.
53. Citterio F, Pozzetto U, Romagnoli J, Tondolo E, Silvestri P, Nanni G, et al. Plasma levels of transforming growth factor-betal in renal transplant recipients receiving different immunosuppressive regimens. Transplant Proc 2004; 36: 698-9.
54. Sadeghi M, Daniel V, Weimer R, Wiesel M, Hergesell O, Opelz G. Pre-transplant Th1 and post-transplant Th2 cytokine patterns are associated with early acute rejection in renal transplant recipients Clin Transplant 2003; 17: 151-7.
55. Webster AC, Playford EG, Higgins G, Chapman JR, Craig J. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2004; (1): CDO03897.
56. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004; 104(3): 649-54.
57. Reddy P, Ferrara JL. Role of interleukin-18 in acute graft-vs-host disease. J Lab Clin Med 2003; 141: 365-71.
58. Wu Q, Fu YX, Sontheimer RD. Blockade of lymphotoxin signaling inhibits the clinical expression of murine graft-versus-host skin disease. J Immunol 2004; 172: 1630-6.
59. Smith XG, Bolton EM, Bradley JA. Targeting IL-15 as a therapeutic strategy in organ transplant rejection. Curr Opin Investig Drugs 2002; 3: 406-10.
60. Szekanecz Z, Koch AE. Therapeutic inhibition of leukocyte recruitment in inflammatory diseases. Curr Opin Pharmacol 2004; 4: 423-8.
61. Demirci G, Gao W, Zheng XX, Malek TR, Strom TB, Li XC. On CD28/CD40 ligand costimulation, common gamma-chain signals, and the alloinumme response. J Immunol 2002; 168: 4382-90.
62. Kirkiles-Smith NC, Mahboubi K, Plescia J, McNiff JM, Karras J, Schechner JS, et al. IL-11 protects human microvascular endothelium from alloinjury in vivo by induction of survivin expression. J Immunol 2004; 172: 1391-1396.
63. Mengle-Graw LJ, Schawrtz BD. Non-steroidal anti-inflammatory drugs. In: Rich RR, Fleisher TA, Shearer WT, Kotzin BL, Schroeder HW. Ed. Clinical Immunology Ptrinciples and Practice. London, Mosby 2001; pp. 107.1-107.10.
64. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol 2002; 23: 144-150.
65. De Gaetano G, Donati MB, Cerletti C. Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. Trends Parmacol Sci 2003; 24: 245-252.
66. Foegh ML, Winchester JF, Zmudka M, Helfrich GB, Cooley C, Rainwell PW, et al. Urine i-TXB2 in renal allograft rejection. Lancet 1981; 2(8244):431-4.
67. Thomas DW, Rocha PN, Nataraj C, Robinson LA, Spurney RF, Koller BH, et al. Proinflammatory actions of thromboxane receptors to enhance cellular immune responses. J Immunol 2003 171(12): 6389-95
68. Morichika T, Takahashi M Iwagaki H, Yagi T, Saito S, Kubo S, et al. Effect of prostaglandin E2 on intercellular adhesion molecule-1 and B7 expression in mixed lymphocyte reaction. Transplantation 2003; 75(12): 2100-5.
69. Takahashi HY, Morichika T, Iwagaki H, Yoshino T, Tamura R, Saito S, et al. Effect of beta 2-adrenergic receptor stimulation on interleukin-18-induced intercellular adhesion molecule-1 expression and cytokine production. J Pharmacol Exp Ther 2003; 304: 634-42.
70. Joshi PC, Zhou X, Cuchens M, Jones Q. Prostaglandin E2 suppressed IL-15-mediated human NK cell function through downregulation of common gamma-chain. J Immunol 2001, 166: 885-91.
71. Takahashi HK, Iwagaki H, Yoshino T, Mori S, Morichika T, Itoh H, et al. Prostaglandin E(2) inhibits IL-18-induced ICAM-1 and B7.2 expression through EP2/EP4 receptors in human peripheral blood mononuclear cells. J Immunol 2002; 168: 4446-54.
72. Garlichs CD, Geis T, Goppelt-Struebe M, Eskafi S, Schmidt A, Schulze-Koops H, et al. Induction of cyclooxygenase-2 and enhanced release of prostaglandin E(2) and I(2) in human endothelial cells by engagement of CD40. Atherosclerosis 2002; 163: 9-16.
73. Dongari-Bagtzoglou AI, Thienel U, Yellin MJ. CD40 ligation triggers COX-2 expression in endothelial cells: evidence that CD40-mediated IL-6 synthesis is COX-2-dependent. Inflamm Res 2003; 52: 18-25.
74. De Sanctis JB, Arciniegas E, Bianco NE. Lipoprotein lipase protects bovine endothelial cells from human NK cytotoxic activity. Cell Immunol 2004; 227: 59-69.
75. Winkelmayer WC, Lorenz M, Kramar R, Fodinger M, Horl WH, Sunder-Plassmann G. C-reactive protein and body mass index independently predict mortality in kidney transplant recipients. Am J Transplant 2004; 4: 1148-54.
76. Inoue Y, Otsuka T, Niiro H, Nagano S, Arinobu Y, Ogami E, et al. Novel regulatory mechanisms of CD40-induced prostanoid synthesis by IL-4 and IIL-10 in human monocytes. J Immunol 2004; 172(4):2147-54
77. Tanaka K, Hirai H, Takano S, Nakamura M, Nagats. K. Effects of prostaglandin D2 on helper T cell functions. Biochem Biophys Res Commun 2004; 316(4): 1009-14.
78. Si Q, Zhao ML, Morgan AC, Brosnan CF, Lee SC. 15-deoxy-Deltal2, 14-prostaglandin J2 inhibits IFN-inducible protein 10/CXC chemokine ligand 10 expression in human microglia: mechanisms and implications. J Immunol 2004; 173: 3 504-13.
79. Clark RB. The role of PPARs in inflammation and immunity. J Leukoc Biol 2002; 71: 3 88-400.
80. Jin S, Mathis AS, Rosenblatt J, Minko T, Friedman GS, Gioia K, et al. Insights into cyclosporine A-induced atherosclerotic risk in transplant recipients: macrophage scavenger receptor regulation. Transplantation 2004; 77: 497-504.
81. Chen G, Wei Q, Wang XM, Wang WY, Xiong YL, Chen S. TMVA, a novel GPIb-binding protein, significantly prevents platelet microthrombi formation and prolongs discordant cardiac xenograft survival. Xenotransplantation 2004; 11: 203-9.
82. Yopp AC, Randolph GJ, Bromberg. Leukotrienes, Sphingolipids, and leukocyte trafficking. J Immunol 2003; 171: 5-10.
83. Wenzel SE. Leukotriene ihibitors. In: Rich RR, Fleisher TA, Shearer WT, Kotzin BL, Schroeder HW. Ed. Clinical Immunology Ptrinciples and Practice. London, Mosby 2001; pp. 108.1-108.7.
84. Tager AM, Bromley SK, Medoff BD, Islam SA, Bercury SD, Friedrich EB, et al. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol 2003; 4: 982-90.
85. Gualde N, Harizi H. Prostanoids and their receptors that modulate dendritic cell-mediated immunity. Immunol Cell Biol 2004; 82: 353-60.
86. Weringer EJ, Perry BD, Sawyer PS, Gilman SC, Showell HJ. Antagonizing leukotriene B4 receptors delays cardiac allograft rejection in mice. Transplantation 1999; 67(6): 808-15.
87. Honig SM, Fu S, Mao X, Yopp A, Gunn MD, Randolph GJ, et al. FTY720 stimulates multidrug transporter and cysteinyl leukotriene dependent T cell chernotaxis to lymph nodes. J. Clin Invest 2003; 111: 627-637.
88. Yopp AC, Fu S, Honig SM, Randolph GJ, Ding Y, Krieger NR, et al. FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J Immunol 2004; 173: 855-65.
89. Lawrence T, Willoughby DA, Gilroy DW. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Immunol 2002; 2, 787-795.
90. Budde K, Schmouder RL, Brunkhorst R, Nashan B, Lucker PW, Mayer T, et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002; 13: 1073-83.
91. Ortaldo JR, Young HA, Winkler-Pickett RT, Bere EW Jr, Murphy WJ, Wiltrout RH. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J Immunol 2004; 172: 943-53.
92. Kobashigawa JA. Targeting non alloimmune-dependent pathways. Transplant Proc 1997; 29(8A): 47S-50S.
93. Katznelson S. Effect of HMG-CoA reductase inhibitors on chronic allograft rejection. Kidney Int Suppl 1999; 71: S117-21.
94. Mach F. Statins as immunomodulators Transpl Immunol 2002; 9: 197-200.
95. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109(23 Suppl 1): II150-7.
96. Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004; 173(l): 1-12.
97. Liao JK, Laufs U. Pleiotropic effect of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
98. Blankenberg FG. Recent advances in the imaging of programmed cell death. Curr Pharm Des 2004; 10(13): 1457-67
99. Jacobsohn DA, Vogelsang GB. Anti-cytokine therapy for the treatment of graft-versus-host disease. Curr Pharm Des 2004; 10(11): 1195-205.
100. Tornita N, Morishita R. Antisense oligonucleotides as a powerful molecular strategy for gene therapy in cardiovascular diseases. Curr Pharm Des 2004, 10(7): 797-803.